About SAB Biotherapeutics, Inc.
https://www.sabbiotherapeutics.comSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.
CEO
Samuel J. Reich
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-05 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIVO CAPITAL, LLC
Shares:11.42M
Value:$45.68M
RA CAPITAL MANAGEMENT, L.P.
Shares:4.4M
Value:$17.61M
COMMODORE CAPITAL LP
Shares:4.4M
Value:$17.61M
Summary
Showing Top 3 of 41
About SAB Biotherapeutics, Inc.
https://www.sabbiotherapeutics.comSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $11.91M ▲ | $5.34M ▲ | 0% | $0.5 ▲ | $46.25M ▲ |
| Q2-2025 | $0 | $8.91M ▼ | $-10.11M ▼ | 0% | $-1.09 ▼ | $-9.23M ▼ |
| Q1-2025 | $0 ▼ | $9.99M ▲ | $-5.2M ▲ | 0% ▲ | $-0.56 ▲ | $-4.35M ▲ |
| Q4-2024 | $114.7K ▲ | $9.34M ▼ | $-11.39M ▼ | -9.93K% ▼ | $-1.23 ▼ | $-10.54M ▼ |
| Q3-2024 | $0 | $10.34M | $-10.35M | 0% | $-1.12 | $-9.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $110.88M ▲ | $183.45M ▲ | $18.37M ▲ | $165.07M ▲ |
| Q2-2025 | $5.71M ▼ | $30.13M ▼ | $18.11M ▲ | $12.02M ▼ |
| Q1-2025 | $12.85M ▼ | $38.12M ▼ | $16.71M ▼ | $21.41M ▼ |
| Q4-2024 | $20.76M ▼ | $44.2M ▼ | $18.23M ▲ | $25.97M ▼ |
| Q3-2024 | $30.4M | $53.8M | $16.89M | $36.9M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.34M ▲ | $-13.05M ▼ | $-129.87M ▼ | $168.69M ▲ | $25.73M ▲ | $-13.05M ▼ |
| Q2-2025 | $-10.11M ▼ | $-7.15M ▲ | $5.2M ▲ | $-173.84K ▲ | $-1.95M ▲ | $-7.15M ▲ |
| Q1-2025 | $-5.2M ▲ | $-7.8M ▲ | $4.67M ▼ | $-173.99K ▼ | $-3.26M ▼ | $-7.8M ▲ |
| Q4-2024 | $-11.39M ▼ | $-9.27M ▼ | $9.33M ▲ | $-44.14K ▲ | $-273.21K ▲ | $-9.33M ▼ |
| Q3-2024 | $-10.35M | $-6.29M | $-1.15M | $-674.13K | $-8.07M | $-6.39M |
Revenue by Products
| Product | Q1-2022 | Q2-2022 | Q3-2022 |
|---|---|---|---|
 Grant Revenue | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
CEO
Samuel J. Reich
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-05 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIVO CAPITAL, LLC
Shares:11.42M
Value:$45.68M
RA CAPITAL MANAGEMENT, L.P.
Shares:4.4M
Value:$17.61M
COMMODORE CAPITAL LP
Shares:4.4M
Value:$17.61M
Summary
Showing Top 3 of 41